Dupilumab Adverse Events in Nasal Polyp Treatment: Analysis of FDA Adverse Event Reporting System
Copyright policy )Dupilumab Adverse Events in Nasal Polyp Treatment: Analysis of FDA Adverse Event Reporting System
ObjectivesDupilumab was the first biologic approved to treat chronic rhinosinusitis with nasal polyps (CRSwNP). While the risk of adverse events in phase‐III clinical trials was low, dupilumab‐associated adverse reactions (DAR) with real‐world use is unknown and potentially under‐reported. We aimed to evaluate DAR for CRSwNP treatment (CRSwNP‐tx) using the FDA Adverse Event Reporting System (FAERS).Study DesignRetrospective database study.MethodsFAERS was queried for DAR from 2019Q1 to 2021Q2. Individual DAR (iDAR) were categorized and quantitatively compared between treatment groups (CRSwNP, asthma, atopic dermatitis). Zero‐truncated Poisson regression was modeled to predict the number of iDAR, and logistic regression was modeled to predict serious DARs.ResultsThere were 15,411 DAR observations; 911 for CRSwNP‐tx, of which 121 (13.3%) had serious reactions and 3 died. Common CRSwNP‐tx iDAR were dermatologic (13.9%), generalized (13.3%), and injection‐site (10.8%) symptoms. The number of CRSwNP‐tx iDAR was 2.99 [2.81, 3.17], compared to 3.44 [3.32, 3.56] for asthma and 3.18 [3.13, 3.24] for atopic dermatitis (Kruskal‐Wallis test, P < .001). For CRSwNP‐tx, iDAR reported‐risk‐ratio was 0.84 [0.77, 0.92] among men and 1.12 [1.04, 1.22] among older adults (>50). Serious DAR reported‐odds‐ratio was 1.37 [0.91, 2.04] among men and 1.39 [0.93, 2.08] among older adults.ConclusionsWhile there are limitations with FAERS, this analysis suggests CRSwNP‐tx is associated with fewer iDAR compared with other treatment indications. More iDAR are experienced among women and older adults, but men tend to have more serious DAR.Level of Evidence3 Laryngoscope, 132:2307–2313, 2022
- University of Pennsylvania United States
- University of California, Riverside United States
Male, Antibodies, Monoclonal, Humanized, Asthma, Dermatitis, Atopic, Nasal Polyps, Clinical Trials, Phase III as Topic, Chronic Disease, Humans, Female, Sinusitis, Aged, Retrospective Studies
Male, Antibodies, Monoclonal, Humanized, Asthma, Dermatitis, Atopic, Nasal Polyps, Clinical Trials, Phase III as Topic, Chronic Disease, Humans, Female, Sinusitis, Aged, Retrospective Studies
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).22 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!